QOL better with carboplatin + paclitaxel for ovarian cancer

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.498, 2006-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Age does not appear to be a barrier to aggressive therapy with paclitaxel and carboplatin in women with ovarian cancer

Inpharma, Vol. 1, Iss. 1224, 2000-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Paclitaxel poliglumex for ovarian cancer

By Galic Vijaya L Wright Jason D Lewin Sharyn N Herzog Thomas J

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 6, 2011-06 ,pp. : 813-821

Informa Healthcare

Access to resources Recommend Favorite

Paclitaxel + carboplatin, docetaxel alone, for endometrial cancer

Inpharma, Vol. 1, Iss. 1579, 2007-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Carboplatin increases efficacy of paclitaxel/trastuzumab in breast cancer

Inpharma, Vol. 1, Iss. 1375, 2003-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

QOL benefits with palliative chemotherapy in ovarian cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 307, 2001-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite